Daily Guardian
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
What's On

Here are the 10 deals worth grabbing from Best Buy’s winter sales event

January 18, 2026

Kaoss Pad V is the first major upgrade to Korg’s touch-based effects in 13 years

January 18, 2026

DeFi Protocol Mutuum Finance (MUTM) Progresses Through Roadmap Phase 2 with Halborn Audit Finalized

January 18, 2026

New Cryptocurrency Mutuum Finance Records 300% MUTM Growth as Phase 7 is Accelerating

January 18, 2026

New Crypto Mutuum Finance (MUTM) Reaches Over 18,700 Investors and $19.8M Raises as Protocol Launch Nears

January 18, 2026
Facebook X (Twitter) Instagram
Finance Pro
Facebook X (Twitter) Instagram
Daily Guardian
Subscribe
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
Daily Guardian
Home » A Race Against Blindness Awards Additional $1.1 Million Grant to Ensure Advancement of AXV-101 into Clinical Trial for Bardet-Biedl Syndrome 1 (BBS1)
Press Release

A Race Against Blindness Awards Additional $1.1 Million Grant to Ensure Advancement of AXV-101 into Clinical Trial for Bardet-Biedl Syndrome 1 (BBS1)

By News RoomJanuary 6, 20263 Mins Read
A Race Against Blindness Awards Additional .1 Million Grant to Ensure Advancement of AXV-101 into Clinical Trial for Bardet-Biedl Syndrome 1 (BBS1)
Share
Facebook Twitter LinkedIn Pinterest Email
A Race Against Blindness Awards Additional .1 Million Grant to Ensure Advancement of AXV-101 into Clinical Trial for Bardet-Biedl Syndrome 1 (BBS1)

GILBERT, Ariz., Jan. 06, 2026 (GLOBE NEWSWIRE) — A Race Against Blindness, the Arizona-based 501(c)(3) nonprofit founded by Dr. Stephen Johnston and Kristina Johnston, today announced  $1.1 million in new grant funding to Axovia Therapeutics, closing a critical funding gap needed for the launch of the AXV-101 clinical trial, an investigational therapy aimed at treating vision loss associated with Bardet-Biedl Syndrome 1 (BBS1). This latest funding brings A Race Against Blindness’s total commitment for AXV-101 to $5.1 million.

The AXV-101 clinical trial received Clinical Trial Application (CTA) clearance during the third quarter of 2025. Despite this regulatory milestone, the trial could not move forward due to a remaining funding gap. The newly announced $1.1 million grant closes that gap, providing the vital funds needed to initiate the trial, which is now expected to begin in early 2026.

“This funding is a crucial milestone in bringing this investigational therapy into the clinic in the coming months,” said Prof. Phil Beales, Chief Executive Officer and Co-Founder of Axovia Therapeutics. “Our planned clinical trial is a first-in-human open-label dose-escalation trial, and as such, we’re moving forward with both urgency and care. We know how much uncertainty families face when they hear this diagnosis. Our goal is simple but powerful: to carefully explore whether this gene therapy can stop retinal degeneration, and, in time, change what it means to live with BBS1-related vision loss.”

A Race Against Blindness has played a central role in funding the advancement of AXV-101 from preclinical development through Clinical Trial Application (CTA) clearance, exemplifying its mission-driven approach to accelerating therapies for rare pediatric eye diseases.

“This commitment reflects our belief that promising therapies should not stall at the threshold of human trials due to lack of funding,” said Stephen Johnston, MD, MBA, Co-Founder of A Race Against Blindness. “This has been a deeply personal mission over the last 3 years, and to now be at this milestone leaves me full of gratitude and hope. The generosity of our supporters is both humbling and a beacon of light for what can be accomplished when people come together around a cause.”

About A Race Against Blindness

A Race Against Blindness is a family-run nonprofit founded by Stephen and Kristina Johnston after learning that their son has Retinitis Pigmentosa caused by Bardet-Biedl Syndrome, a rare condition leading to progressive vision loss in children. Their family has transformed a personal diagnosis into a mission to accelerate treatments for blinding diseases. Established to address the critical gap that often prevents promising vision therapies from reaching patients, A Race Against Blindness provides targeted, milestone-driven funding to move high-impact programs from the laboratory into human clinical trials.

Contact:

Dr. Stephen Johnston

Co-Founder & President

A Race Against Blindness

Email: [email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/7487533c-7966-4edf-a94c-662278b9a14d

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

Keep Reading

DeFi Protocol Mutuum Finance (MUTM) Progresses Through Roadmap Phase 2 with Halborn Audit Finalized

New Cryptocurrency Mutuum Finance Records 300% MUTM Growth as Phase 7 is Accelerating

New Crypto Mutuum Finance (MUTM) Reaches Over 18,700 Investors and $19.8M Raises as Protocol Launch Nears

NeuroDyne Drops: Sharp Mind, Enhanced Memory, and Lasting Focus – As Nature Intended, Ingredients

Optivell Officially Announced as a Vision Support Formula for Preventive Eye Wellness

Phentermine Over the Counter Alternative 2026 – OTC Appetite Suppressant Search Trend Analysis Positions PhenQ as a Market Leader According to 1200 Doctors

Sugar Clean Drops: Top Blood Sugar Support Supplement for Metabolic Wellness and Energy Support

CryptSync Launches Insured Self-Custody Wallet With Seedless Onboarding and Social Payments

ProCryptoRecovery LTD Unveils Platform, Advancing AI-Driven Crypto Forensics and Compliance-Ready Investigations

Editors Picks

Kaoss Pad V is the first major upgrade to Korg’s touch-based effects in 13 years

January 18, 2026

DeFi Protocol Mutuum Finance (MUTM) Progresses Through Roadmap Phase 2 with Halborn Audit Finalized

January 18, 2026

New Cryptocurrency Mutuum Finance Records 300% MUTM Growth as Phase 7 is Accelerating

January 18, 2026

New Crypto Mutuum Finance (MUTM) Reaches Over 18,700 Investors and $19.8M Raises as Protocol Launch Nears

January 18, 2026

Subscribe to News

Get the latest Canada news and updates directly to your inbox.

Latest News

Political analyst reacts to Canada’s tariff deal with China

January 17, 2026

Langdon residents step up to help family displaced by fire

January 17, 2026

Canada launches compensation program for banned assault-style firearms

January 17, 2026
Facebook X (Twitter) Pinterest TikTok Instagram
© 2026 Daily Guardian Canada. All Rights Reserved.
  • Privacy Policy
  • Terms
  • Advertise
  • Contact

Type above and press Enter to search. Press Esc to cancel.

Go to mobile version